Furthermore, preclinical studies testing the combination of sclerostin antibodies with anti-MM drugs, such as bortezomib and dexamethasone, found that these antibodies did not affect or interfere with the anti-MM activity of drugs. The gene discussed is SOST; the disease is Miyoshi myopathy.